Four Bluejay shares will become one on Nov. 3

Bluejay Diagnostics (NASDAQ: BJDX) announced a 1-for-4 reverse stock split, effective November 3, 2026. The company's common stock will trade under the same symbol, BJDX, with a new CUSIP number. Shareholders with certificates will receive exchange instructions, while others will see changes reflected in their accounts. Bluejay focuses on medical diagnostics, including its Symphony™ System for sepsis triage, which awaits FDA approval.

Original reporting
Published Oct 30, 2026, 2:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 2:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$BJDX
Neutral
high confidence
Mentioned
$BJDX
Relevance
6/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$BJDXNeutralMed
01

Why it matters

The reverse split changes the share count by a factor of four while leaving par value unchanged, which can alter per-share valuation metrics and short-term liquidity/volatility dynamics around Nov. 3.

02

Market read

This is a discrete corporate-action catalyst with a known effective date, making it actionable for positioning around the split and for managing liquidity and order execution expectations.

03

What to watch

Traders should monitor broker processing and any temporary trading frictions around the effective date, since holders in certificate form must exchange shares while book-entry holders typically see the change automatically.

Relevance 6/10Novelty 7/10Timing: Effective at 12:01 a.m. ET on Nov. 3, with post-split trading starting that morning.

Background

Bluejay Diagnostics is a near-patient diagnostics company with its Symphony platform and an IL-6 test candidate; the release notes it lacks US regulatory clearance for Symphony.

Company-level read

Ticker impact

$BJDXNeutralHigh confidence
Context

Bluejay Diagnostics approved a 1-for-4 reverse stock split effective Nov. 3, which can materially affect share price, liquidity, and Nasdaq trading optics.

Expected impact

Likely near-term volatility and potential downward pressure if the market interprets the move as a continued capital-market stress signal, with the main driver being the mechanical share-count change and liquidity optics.

Evidence & confidence

The article discloses the exact reverse split ratio and the effective trading date (Nov. 3) but provides no fundamental operational update; reverse splits commonly change per-share pricing and can affect investor perception and liquidity.

Market effects

For medical diagnostics microcaps, reverse splits can reflect ongoing financing or compliance pressures, potentially influencing sentiment toward similar pre-revenue or regulatory-stage names.

Primarily impacts US small-cap/Nasdaq Capital Market trading flows for the issuer.

Limited, as the event is company-specific and US-market microstructure driven.

Counterpoint

The reverse split may be a technical step to maintain listing compliance or improve trading liquidity, not necessarily a deterioration in fundamentals.

Key entities

  • Bluejay Diagnostics, Inc.

    NASDAQ-listed medical diagnostics company announcing a 1-for-4 reverse stock split effective Nov. 3, 2026.

  • Continental Stock Transfer & Trust Company

    Transfer agent retained to act as exchange agent for the reverse stock split.

  • Nasdaq Capital Market

    Exchange where the stock will open for trading on a post-split basis on Nov. 3, 2026.

Related articles

$BJDXMed

Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update Completes SYMON-II clinical study enrollment and advances clinical validation activities Achieves critical manufacturing milestone ahead of contractual deadline, strengtheni

$BJDXMedAI 8/10

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 For Immediate Release Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock. SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Towar

$BJDXMedAI 8/10

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics (NASDAQ:BJDX) announced baseline clinical data from its SYMON-II study, evaluating IL-6 as a biomarker for 28-day mortality risk in sepsis patients. The study included 777 patients, with an 18% mortality rate. The company aims to use this data to support a regulatory submission for its Symphony IL-6 Test, which is not yet FDA-approved.